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SUMMARY
Genomic damage can feature DNA-protein cross-
links whereby their acute accumulation is utilized to
treat cancer and progressive accumulation causes
neurodegeneration. This is typified by tyrosyl DNA
phosphodiesterase 1 (TDP1), which repairs topo-
isomerase-mediated chromosomal breaks. Although
TDP1 levels vary in multiple clinical settings, the
mechanism underpinning this variation is unknown.
We reveal that TDP1 is controlled by ubiquitylation
and identify UCHL3 as the deubiquitylase that con-
trols TDP1 proteostasis. Depletion of UCHL3 in-
creases TDP1 ubiquitylation and turnover rate and
sensitizes cells to TOP1 poisons. Overexpression of
UCHL3, but not a catalytically inactive mutant,
suppresses TDP1 ubiquitylation and turnover rate.
TDP1 overexpression in the topoisomerase ther-
apy-resistant rhabdomyosarcoma is driven by
UCHL3 overexpression. In contrast, UCHL3 is down-
regulated in spinocerebellar ataxia with axonal neu-
ropathy (SCAN1), causing elevated levels of TDP1
ubiquitylation and faster turnover rate. These data
establish UCHL3 as a regulator of TDP1 proteostasis
and, consequently, a fine-tuner of protein-linked
DNA break repair.
INTRODUCTION
Optimal protein homeostasis (proteostasis) is essential for all
aspects of cellular activities. It is controlled by a number of
competing, but integrated, pathways including biogenesis, traf-
ficking, and degradation (Balch et al., 2008; Meerang et al.,
2011). Adjusting these processes to the demand of individual
proteins and pathways is essential to maintain cellular function.
Perturbation in proteostasis causes human disease. For
example, failure to degrade and subsequently clear proteins
that are covalently linked to DNA cause human neurological
disease and premature aging (El-Khamisy et al., 2005; Go´mez-
Herreros et al., 2014; Rubinsztein, 2006; Vaz et al., 2016; Walker
et al., 2017). The linkage of proteins to DNA could be non-enzy-
matically driven by the vicinity of proteins to DNA in the presence
of endogenous crosslinking agents, such as aldehydes. Formal-
dehyde is a potent crosslinking agent generated as a metabolic
by-product during de-methylation of histones and DNA (Shi
et al., 2004; Trewick et al., 2002). It could also be driven enzymat-
ically, as part of physiological cycles of many DNA metabolising
enzymes, such as topoisomerases, DNA glycosylases, and
methyltransferases (Kiianitsa and Maizels, 2013). This linkage
is generally transient and reversible, but it can become irrevers-
ible under certain physiological and pathological circumstances,
causing deleterious protein-liked DNA breaks (PDBs). The most
famous example of PDBs is those mediated by DNA topoiso-
merases (Ashour et al., 2015; Chiang et al., 2017; Pommier
et al., 2016).
Topoisomerases are elegant biological tools that overcome
topological entanglements inherent to the intertwined and
compact nature of DNA. Their function is important for many as-
pects of DNAmetabolism, such as gene transcription, DNA repli-
cation, recombination, and repair (Champoux and Dulbecco,
1972). Topoisomerases achieve this by transiently cleaving one
or two strands of the DNA, thereby allowing the swiveling or rota-
tion of the other strand or duplex around the break. Topoisomer-
ase I (TOP1) generates intermediates in which the TOP1 is linked
to the 30 terminus of a single-strand break (SSB), whereas TOP2
intermediates are linked to the 50 termini of a DNA double-strand
break (DSB). Accumulation of TOP1- or TOP2-mediated PDBs
cause neurological disease in humans (Katyal et al., 2014, Ala-
goz et al., 2013; El-Khamisy et al., 2005; Go´mez-Herreros
et al., 2014; Walker and El-Khamisy, 2018) and has been widely
exploited in cancer chemotherapy (Alagoz et al., 2014; Ashour
et al., 2015; Das et al., 2014; Meisenberg et al., 2017; Rehman
et al., 2018). Accumulation of PDBs is counteracted by a number
of PDB repair activities that constantly monitor and precisely
disjoin the stalled topoisomerase from DNA termini or nucleolyti-
cally cut the DNA to release the stalled topoisomerase and a
fragment of DNA. The former mode of repair spares the loss of
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genetic information and is conducted by a class of enzymes that
specifically cleave the covalent linkage between the stalled
topoisomerase and DNA called ‘‘tyrosyl DNA phosphodiester-
ases’’ (TDPs). TDP1 primarily disjoins stalled TOP1 peptides
from PDBs, whereas TDP2 exhibits greater preference toward
TOP2-mediated PDBs (El-Khamisy et al., 2005; Cortes Ledesma
et al., 2009; Schellenberg et al., 2017). Defects in either TDP1 or
TDP2 cause accumulation of PDBs and interfere with transcrip-
tion, leading to neuronal cell death (Go´mez-Herreros et al., 2014;
Hudson et al., 2012, Katyal et al., 2007). In contrast, their overex-
pression has been linked to the resistance of cancer cells to
topoisomerase targeting therapies (Barthelmes et al., 2004; Do
et al., 2012; Duffy et al., 2016; Liu et al., 2007; Meisenberg
et al., 2014). Despite their roles in many aspects of cellular activ-
Figure 1. TDP1 Is Covalently Modified by
Ubiquitin and Its Ubiquitylation Is Controlled
by UCHL3
(A) HEK293T cells were transfected with plasmids
encoding Flag-TDP1 and empty vector ‘‘Ubi’’ or a
vector encoding His-ubiquitin ‘‘+Ubi.’’ Cells were
treated with 30J UV irradiation and allowed to
recover for 1 hr. Ubiquitinated proteins were purified
by Ni-pull-down and analyzed by immunoblotting.
(B) HEK293T cells were transfected with plasmids
encoding Myc-TDP1 and His-ubiquitin. Ubiquiti-
nated proteins were purified by Ni-pull-down and
analyzed by anti-Myc immunoblotting.
(C) Diagram depicting purification of ubiquitinated
TDP1 from mammalian cells.
(D) HEK293T cells were transfected with plasmids
encoding Myc-TDP1 and His-ubiquitin. Ubiquiti-
nated proteins were purified by Ni-pull-down and
Ni-bound proteins were eluted with imidazole
‘‘eluate’’ and subjected to immunoprecipitation with
anti-Myc antibodies.
(E) HEK293T cells were transfected with a plasmid
encoding Myc-TDP1 and hemagglutinin (HA)-tag-
ged wild-type ubiquitin ‘‘WT’’ or ubiquitin mutant in
which all lysines were replaced by arginine ‘‘K0’’ or a
mutant in which all lysines were replaced by argi-
nine, except K48 ‘‘K48’’ or K63 ‘‘K63’’. HA immu-
noprecipitates were purified using anti-HA anti-
bodies and analyzed by anti-Myc immunoblotting.
(F) A scheme depicting the siRNA DUB screen.
(G) The DUB screen was repeated four times, and a
representative immunoblot is shown (left). TDP1
ubiquitylation was quantified following normalization
to TDP1 and is presented as average a.u. ± SEM
(right). Asterisks denote p < 0.001; Student’s t test.
(H) HEK293T cells were transfected with UCHL3
siRNA ‘‘UCHL3’’ or scrambled non-targeting siRNA
‘‘control,’’ and transfection was repeated after 48 hr,
followed by cell lysis in SDS-denaturing buffer after
another 24 hr. Endogenous TDP1 was analyzed by
immunoblotting.
ities and their implication in multiple clinical
settings, the mechanisms that maintain
TDPs proteostasis are not known.
TDP1 proteostasis is particularly attrac-
tive since a specific mutation in its active
site that substitutes histidine 493 to arginine perturbs the
completion of its catalytic cycle and additionally produces a
TDP1-mediated PDB (Cuya et al., 2016; Interthal et al., 2005).
Bi-allelic TDP1H493R mutation is associated with 70% reduc-
tion of TDP1 protein level and leads to the accumulation
of both TOP1- and TDP1-mediated PDBs, causing neurodeger-
ation in spinocerebellar ataxia with axonal neuropathy 1
(SCAN1). Cells derived from SCAN1 patients exhibit marked
sensitivity to TOP1 poisons, such as camptothecin and irinote-
can (El-Khamisy et al., 2005; Interthal et al., 2005; Miao et al.,
2006; Zhou et al., 2005). Although much is known about TDP1
biology, little is known about the mechanisms that control its
steady-state level and why levels are markedly reduced in
SCAN1 remains unexplained.
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Figure 2. UCHL3 Is a Topoisomerase-Linked DNA Break Repair Factor
(A) HEK293T cells were transfected with UCHL3 siRNA ‘‘UCHL3’’ or scrambled non-targeting siRNA ‘‘control,’’ followed by incubation with 100 mg/mL cyclo-
heximide ‘‘CHX’’ for the indicated time periods. Endogenous levels of TDP1 were assessed by immunoblotting and quantified following normalization to tubulin
and presented as an average a.u. ± SEM from three biological replicates.
(legend continued on next page)
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Post-translational modifications have been shown to control
the steady-state level and modulate the function of several
DNA repair factors (Elserafy and El-Khamisy, 2018; Meisenberg
et al., 2012; Parsons et al., 2008). Protein ubiquitylation plays an
important role in controlling the half-life of proteins via the ubiq-
uitin-proteasome system (Amm et al., 2014). It offers a reversible
mode of control for a myriad of cellular processes such as pro-
tein sorting, signal transduction and DNA repair (Chen and
Chen, 2013; Francisco et al., 2014; Meisenberg et al., 2012; Par-
sons et al., 2008, 2009; van Cuijk et al., 2014). The transient
nature and fine tuning of ubiquitylation is achieved by an intricate
balance of two opposing activities: the ubiquitin-conjugating
cascade, which is a complex set of enzymes that conjugate
ubiquitin to proteins, and deubiquitylase enzymes (DUBs),
which remove ubiquitin molecules from the modified proteins
(Komander et al., 2009; Metzger et al., 2014). Here, we report
that TDP1 levels are regulated by ubiquitylation and identify
UCHL3 as the deubiquitylase enzyme controlling TDP1 proteo-
stasis. A low level of UCHL3 is associated with reduced TDP1
protein levels, causing neurological disease, whereas its overex-
pression causes higher TDP1 levels in cancer.
RESULTS
TDP1 overexpression in cancer is linked to resistance to topo-
isomerase I (TOP1)-targeting therapies (Duffy et al., 2016; Liu
et al., 2007), and its reduced expression is linked to mutations
that cause neurological disease (El-Khamisy et al., 2005; Taka-
shima et al., 2002). To test whether TDP1 is a substrate for ubiq-
uitylation, we transfected HEK293T cells with plasmids encoding
Flag-TDP1 and empty vector or a vector encoding His-ubiquitin.
Ubiquitinated proteins were purified by Ni-pull-down and frac-
tionated on SDS-PAGE. As previously reported (Kannouche
and Lehmann, 2004; Kannouche et al., 2004), a slower migrating
band was observed for PCNA, a finding that is consistent with its
ubiquitylation since itwasdependent onUV irradiation (Figure1A,
lane 5). A slower migrating band was also observed for Flag-
TDP1, which was only present in samples containing His-ubiqui-
tin, suggesting that TDP1 is a substrate for ubiquitylation (Fig-
ure 1A, lanes 5 and 6). We noticed un-ubiquitylated Flag-TDP1
and PCNA coming down in the Ni-pull-down, which was not the
case by repeating the experiment using Myc-TDP1 and more
stringent pull-down conditions (Figure 1B). Next, we purified
ubiquitinated proteins using Ni-pull-down, followed by elution
with imidazole and the pool of ubiquitinated proteins was then
subjected to immunoprecipitation using anti-Myc antibodies.
This double purification method revealed a distinct band that
was present in samples containing Myc-TDP1 and His-ubiquitin,
but not Myc-TDP1 and empty His vector (Figures 1C and 1D),
confirming that TDP1 is ubiquitinated in mammalian cells. Trans-
fection with a ubiquitin mutant in which all lysine residues were
replaced by arginine, except K48, led to less enrichement of
monoubiquitinated TDP1compared to ubiquitinmutants inwhich
all lysines were replaced by arginine except K63 (Figure 1E), sug-
gesting a role for ubiquitylation in controlling TDP1 proteostasis.
In silico analysis of TDP1 sequence using the ubiquitin site pre-
diction toolsUbPred,CKSAAP,andBDM-PUBrevealedK186and
K425 as potential ubiquitylation sites. However,mutation of either
or both residues to arginine did not abrogate TDP1 ubiquitylation
(Figure S1A). Subjecting purified ubiquitinated TDP1 described in
Figure 1D to mass spectrometric analysis using maXis HUR-TOF
and a Q Exactive HF hybrid quadrupole orbitrap, in several other
attempts, Thermo Orbitrap spectrometers, identified lysine 114
as a potential site. Mutant variants of TDP1 were generated at
K114 and the nearby lysine residue K112 in addition to the known
SUMOylation site K111, either separately or in combination (Fig-
ure S1B). However, none of the above attempts were successful,
likely because of secondary ubiquitylation sites that can compen-
sate if the primary site is lost.We therefore decided to study TDP1
ubiquitylation by identifying the deubiquitylase (DUB) activity. A
small interferingRNA (siRNA)DUBscreenwasperformed inwhich
HEK293T cells were transfected with a plasmid encoding His-
ubiquitin and Myc-TDP1 and then reverse transfected with an
siRNA OnTarget Plus pooled library of all reported DUBs (Fig-
ure 1F). The DUB screen was repeated four times, and, doing
so, revealed the ubiquitin carboxyl-terminal hydrolase isozyme
L3 (UCHL3) as the most consistent hit (Figures 1G and S2). Pro-
longed depletion of UCHL3 using an independent pool of siRNA
led toamarked reductionofendogenousTDP1andaconcomitant
increase in slower-migrating bands, suggesting increased TDP1
ubiquitylation (Figure 1H).
To examine if the increased TDP1 ubiquitylation caused by
UCHL3depletionwould lead to increased turnover, wemonitored
the TDP1 protein level following incubations with the protein
(B) HEK293T cells transfected with UCHL3 or non-targeting siRNA were analyzed by immunoblotting (top). TDP1 and UCHL3 mRNA were normalized to GAPDH
from three biological replicates and presented as average ± SEM (bottom).
(C) HEK293T cells transfected with UCHL3 siRNA ‘‘UCHL3’’ or scrambled non-targeting siRNA ‘‘control’’ were treated with 1 mMCPT for 30 min, and the number
of cells positive for 53BP1 foci (containing more than 5 foci) were counted and presented as a percentage of total cells (left). The percentage of cells positive for
53BP1 was quantified at the indicted repair time points (right). Data are the average of three biological replicates ± SEM.
(D) MRC5 cells were transfected with UCHL3 siRNA ‘‘UCHL3’’ or scrambled non-targeting siRNA ‘‘control’’ followed by incubation with the indicated concen-
trations of CPT for 1 hr, and survival was calculated from the average of three biological replicates ± SEM.
(E) Chromosomal DNA breaks were quantified by alkaline comet assays, and data represent the average of three biological replicates ±SEM. 150 cells scored per
experiment.
(F) HEK293T cells expressing Myc-TDP1 were incubated with cycloheximide ‘‘CHX’’ alone or additionally with the transcription inhibitor, DRB, for the indicated
time periods andMyc-TDP1 levels were assessed by immunoblotting. The remaining TDP1, following normalization to actin, was calculated from three biological
replicates and presented as average ± SEM.
(G) HEK293T cells were incubated with DMSO or 50 mM DRB, and chromosomal DNA breaks were quantified by alkaline comet assays.
(H) HEK293T cells were transfected with CRSPR/Cas9 and gRNA targeting UCHL3, followed by isolation of two single clones and analyses of cell lysate by
immunoblotting (left). CPT-inducedDNA breaks were quantified using the alkaline comet assay as described in (E) and (G), and data are presented as scatterplots
from three biological replicates. *p < 0.05; **p < 0.01; ***p < 0.001; ns p > 0.05, Student’s t test.
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Figure 3. UCHL3 Is Upregulated in the TDP1-Overexpressing Rhabdomyosarcoma Cells and Its Depletion Restores TDP1 Levels
(A) Control ‘‘HSMM’’ and rhabdomyosarcoma ‘‘CW9019’’ cell lysates analyzed by immunoblotting for TDP1 and UCHL3 expression. TDP1 mRNA was quantified
by qPCR and is presented as an average fold change from three biological replicates ± SEM. UCHL3 protein levels were quantified from three biological repeats
and are presented as average ± SEM.
(legend continued on next page)
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synthesis inhibitor cycloheximide. UCHL3-depleted cells ex-
hibited a faster rate of TDP1 turnover (Figure 2A), which was not
due to an indirect impact on transcription, becuase UCHL3-defi-
cient cells showed a reduction in UCHL3 mRNA, but not TDP1
mRNA (Figure 2B). While no difference in TOP1 double-strand
breaks (DSBs) was observed immediately after CPT treatment,
UCHL3-deficient cells exhibited a delay in the kinetics of TOP1-
DSB clearance (Figure 2C). Furthermore, UCHL3-deficient cells
were less able to survive theCPTchallenge compared to controls,
as measured by clonogenic survival assays (Figure 2D). Next, we
quantified TOP1-mediated DNA strand breaks using the alkaline
comet assay, which primarily measures DNA SSBs. Treatment
with the TOP1 poison CPT led to elevation of TOP1-SSBs in
UCHL3-deficient cells compared to controls (Figure 2E). Consis-
tent with a predominant role of TDP1 during transcription (El-Kha-
misy et al., 2005), inhibition of transcription using 5,6-dichloro-1-
b-D-ribofuranosylbenzimidazole (DRB) suppressed the turnover
rateof TDP1 (Figure 2F) andabrogated theUCHL3-dependent dif-
ference in TOP1-SSBs (Figure 2G). Disrupting UCHL3 using
UCHL3 gRNA and CRISPR/Cas9 also led to higher accumulation
of CPT-induced TOP1-SSBs, and the difference was also associ-
ated with active transcription, because it disappeared upon pre-
incubation with DRB (Figure 2H). Together, these data suggest
that UCHL3 is a player during TOP1-mediated DNA repair.
The acute inhibition of TOP1-mediated DNA repair has been
widely exploited to treat various forms of solid tumors (Ashour
etal., 2015;Pommieretal., 2016).However,cancercellscan resist
TOP1 targeting therapies by overexpression of PDB repair factors
such as TDP1. For example, recent elegant work identified TDP1
overexpression in rhabdomyosarcoma (Duffy etal., 2016).Consis-
tent with published data, TDP1 is markedly overexpressed in the
CW9019 rhabdomyosarcoma compared to control cells (Fig-
ure 3A, top). Interestingly, the overexpression was not due to
elevated TDP1mRNA,but, instead,weobserved2.5-fold higher
UCHL3 protein expression (Figure 3A, bottom). Depletion of
UCHL3 in rhabdomyosarcoma cells markedly accelerated TDP1
turnover, as measured by CHX chase experiments (Figure 3B).
In line with UCHL3 overexpression, immunoprecipitation of
endogenous TDP1 revealed lower levels of K48-ubiquitylated
TDP1 in rhabdomyosarcoma compared to control cells (Fig-
ure 3C). Inhibiting the proteasome using MG132 led to marked
enrichment of K48-ubiquitylated TDP1 in control cells but no
impact in rhabdomyosarcoma cells, due to high UCHL3 levels
(Figure 3C). Depletion of UCHL3 was sufficient to reduce TDP1
expression in rhabdomyosarcoma cells to levels comparable to
control cells (Figure 3D, top) and led to hypersensitivity to the
TOP1 poison CPT (Figure 3D, bottom). Consistent with the higher
level of UCHL3 in rhabdomyosarcoma, they exhibited lower levels
of CPT-induced topoisomerase cleavage complexes (TOP1cc),
which were markedly increased upon UCHL3 depletion (Fig-
ure 3E). To ascertain a direct role of UCHL3 during TDP1-medi-
ated repair, we performed epistasis analyses. Co-depletion of
TDP1 and UCHL3 did not lead to more CPT hypersensitivity
compared to depletion of either enzyme alone confirming that
they both act together in the same pathway to repair TOP1-medi-
ated PDBs (Figure 4A). Furthermore, incubation of purified K48-
ubiquitylated TDP1 with recombinant UCHL3 led to reduction of
TDP1ubiquitylation (Figure4B)andaphysical interactionbetween
TDP1 and UCHL3was observed by co-immunoprecipitation (Fig-
ure 4C). Ectopic overexpression of UCHL3 led to stabilization of
TDP1 protein level (Figure 4D), which was not the case for a
UCHL3C95A catalytically inactive mutant (Zhang et al., 2013) (Fig-
ure 4E). Furthermore, catalytic inhibition of UCHL3 led to
increased TDP1 ubiquitylation (Figure 4F). Together, we conclude
that UCHL3 controls PDB repair by regulating TDP1 proteostasis.
In contrast to CPT-resistant cancers, progressive accumula-
tion of PDBs due to TDP1 deficiency leads to neurodegenera-
tion. Mutation of histidine 493 of TDP1 to arginine causes spino-
cerebellar ataxia and axonal neuropathy 1 (SCAN1) (Takashima
et al., 2002). Cells derived from SCAN1 patients exhibit a marked
elevation of PDBs and a significant reduction of TDP1 protein
level (El-Khamisy et al., 2005; Interthal et al., 2005). However,
the reason for this reduction remains unknown. We therefore
wondered whether the TDP1 H493 mutation would be more
prone to ubiquitylation than wild-type TDP1. To test this, we per-
formed Ni-pull-down comparing TDP1, TDP1H493R and another
mutant that has been shown to inhibit the second step of
TDP1 catalytic cycle, TDP1H493N (Interthal et al., 2005). Muta-
tions in H493 that lead to accumulation of PDBs do indeed
render TDP1 more prone to ubiquitylation (Figure 5A). Mutating
all lysines in ubiquitin to arginine except K48 led to reduced en-
richement of monoubiquitinated TDP1H493R (Figure 5B). Consis-
tent with the accumulation of TDP1H493R PDBs during transcrip-
tion, incubation with the transcription inhibitor, DRB, led to a
reduction of TDP1H493R ubiquitylation (Figure 5C). These data
suggest that accumulation of unrepaired PDBs, including DNA-
TDP1H493R breaks during transcription, promotes TDP1H493R
ubiquitylation. To test whether this is true in patient-derived
SCAN1 cells, we monitored TDP1 protein turnover following
treatment with cycloheximide. TDP1H493R in SCAN1 cells ex-
hibited faster rate of degradation compared to wild-type TDP1
(Figure 5D). Treatment with CPT led to stabilization of TDP1 in
(B) CW9019 cells were transfected with scrambled non-targeting control or UCHL3 siRNA and, 48 hr later, were incubated with cycloheximide ‘‘CHX.’’ TDP1
levels were assessed by immunoblotting. Band intensities were quantified and normalized to actin. The remaining TDP1 was calculated relative to levels prior to
CHX incubations from three biological replicates and is presented as average ± SEM.
(C) HSMM and CW9019 cells were pre-incubated with 20 mM MG132 for 4 hr, followed by lysis and purification of TDP1 using anti-TDP1 immunoprecipitation.
TDP1 immunoprecipitates were analyzed by anti-TDP1 and anti-K48 immunoblotting. TDP1 K48 ubiquitylation and TDP1 levels were quantified and presented as
a percentage change of K48/TDP1 ratio.
(D) Cells were transfected with scrambled non-targeting siRNA ‘‘control’’ or UCHL3 siRNA, and transfection was repeated after 48 hr. Cell lysates were collected
24 hr, following the last transfection and analyzed by immunoblotting (top). CW9019 cells were treated with the indicated doses of CPT and survival calculated
using clonogenic survival assays (bottom). Results are averages of three repeats ± SEM.
(E) Cells were transfected with scrambled non-targeting siRNA or UCHL3 siRNA and incubated with 1 mM CPT for 10 min and examined for TOP1cc using anti-
TOP1cc antibodies. Scale bar, 5 mm. Percentage of positive cells with >8 TOP1cc foci were counted from three biological replicates and presented as an
average ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns p > 0.05, Student’s t test.
Cell Reports 23, 3352–3365, June 12, 2018 3357
Figure 4. UCHL3 Acts Together with TDP1 to Regulate Topoisomerase-I-Mediated Chromosomal Break Repair
(A) CW9019 cells were transfected with control non-targeting siRNA, TDP1 siRNA, UCHL3 siRNA, or both TDP1 and UCHL3 siRNA, and cell extracts were
analyzed by immunoblotting (top). Cells transfected with the indicated siRNA were treated with CPT, and survival was calculated using clonogenic survival
assays. Results are averages of four biological repeats ± SEM.
(legend continued on next page)
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wild-type cells, which is consistent with previous reports (Das
et al., 2009); however, it led to a faster rate of degradation in
SCAN1 cells (Figure 5D). Inhibiting the proteasome using
MG132 suppressed the fast rate of TDP1H493R degradation
and led to accumulation of ubiquitylated TDP1H493R species (Fig-
ures 5E and 5F). Purification of endogenous ubiquitylated TDP1
using Multi-DSK (Wilson et al., 2012) followed by TDP1 immuno-
precipitation using anti-TDP1 antibodies revealed a marked in-
crease of endogenous TDP1 ubiquitylation in SCAN1 cells (Fig-
ure 5G). The ubiquitylation of purified K48-ubiquitylated TDP1
from SCAN1 cells was reduced upon treatment with recombi-
nant UCHL3 (Figure 5H). Consistent with this, SCAN1 cells ex-
hibited 50% reduction of UCHL3 expression (Figure 5I).
Replenishing UCHL3 levels in SCAN1 by its ectopic overex-
pression was sufficient to restore TDP1 protein, without affecting
TDP1 mRNA, to levels comparable to control cells (Figure 6A).
Although it may appear beneficial to restore the reduced level
of TDP1 in SCAN1, this variant carries the bi-allelic TDP1H493R
mutation, which generates PDBs featuring both TOP1- and
TDP1-linked DNA breaks. Consistent with this, overexpression
of UCHL3 led to a further increase in PDBs in SCAN1 cells, as
measured by the alkaline comet assay (Figure 6B). It appears
therefore that SCAN1 cells downregulate UCHL3 in an attempt
to avoid the unfavorable outcomes of accumulating further
PDBs. Finally, the accumulation of PDBs is also a feature of other
neurological disorders with defective ATM, such as ataxia telan-
giectasia (A-T) and amyotrophic lateral sclerosis (ALS) (Alagoz
et al., 2013; Katyal et al., 2014; Walker et al., 2017). To test
whether UCHL3 is also downregulated in A-T, we compared mi-
croarray data (GEO: GSE61019) obtained from the cerebellum of
control apparently healthy individuals to those obtained fromA-T
patients (Jiang et al., 2015). Consistent with the SCAN1 patient-
derived data, UCHL3 is also downregulated in the human A-T
cerebellum. Thus, we conclude that UCHL3 is a player in PDB
repair and its level is downregulated in at least two PDB repair-
deficient human neurological disorders.
DISCUSSION
TOP1-mediated PDBs are an important class of DNA single-
strand breaks (SSBs), which are widely exploited in chemo-
therapy (Ashour et al., 2015; Pommier et al., 2016). In contrast,
their progressive accumulation leads to multiple neurological
disorders (Alagoz et al., 2013; El-Khamisy, 2011; Go´mez-Her-
reros et al., 2014; Hudson et al., 2012; Katyal et al., 2014; Kerzen-
dorfer et al., 2010; Walker et al., 2017). TDP1 is a key factor for
repairing TOP1-mediated PDBs and its mutation causes the
demise of post-mitotic tissue and cerebellar ataxia in SCAN1.
Although much is known about the enzymatic and cellular func-
tions of TDP1, it is not known how cells fine-tune its level to sup-
port PDB repair events. Here, we report multiple evidence
showing a direct role of UCHL3 in controlling TDP1 proteostasis:
(1) reduction of K48-ubiquitylated TDP1 in cancer cells overex-
pressing UCHL3, (2) reduction of K48-uibiquitylated TDP1
upon addition of recombinant UCHL3, (3) enrichment of K48-
ubiquitylated TDP1 upon MG132 treatment, which is dependent
on UCHL3 levels, (4) epistatic relationship showing that co-
depletion of TDP1 and UCHL3 does not further sensitize cells
to TOP1 poisons than depletion of either enzyme alone, (5) phys-
ical interaction between TDP1 and UCHL3, and (6) changes in
the ubiquitylation status and TDP1 turnover upon changes in
UCHL3 levels induced by its ectopic overexpression, siRNA
depletion, CRISPR editing, and pharmacologic inhibition and,
also, in two physiologically relevant clinical settings.
Like TOP1 and TDP1, UCHL3 homologs have been identi-
fied across multiple species, suggesting the evolutionarily
conserved nature of this mode of DNA damage repair regulation
(Frickel et al., 2007). Protein ubiquitylation has been shown to
play a key role during DNA damage repair (Jackson and Dur-
ocher, 2013). For example, histone ubiquitylation promotes the
recruitment of DSB repair factors to sites of chromatin damage
(Huen et al., 2007; Doil et al., 2009; Mailand et al., 2007; Mattiroli
et al., 2012), and regulates the level of base excision repair pro-
teins (Meisenberg et al., 2012; Parsons et al., 2008, 2009). Here,
we identify UCHL3 as a regulator for chromosomal SSB repair by
controlling the ubiquitylation status and therefore the steady-
state level of TDP1. UCHL3 is a cysteine protease featuring a
classical Cys-His-Asp catalytic triad. There is a precedent for
the involvement of UCHL3 in controlling steady-state levels of
proteins in other cellular processes. For example, UCHL3 phys-
ically interacts with Smad1 and decreases its poly-ubiquitylation
(Kim et al., 2011). Consequently, it was suggested that UCHL3
stabilizes Smad1 signaling, which may explain the enhanced
osteoblast differentiation caused by UCHL3 overexpression
(Kim et al., 2011). Deletion of Uchl3 in mice led to marked accu-
mulation of poly-ubiquitinated proteins (Setsuie et al., 2010).
This accumulation was due to UCHL3 catalytic activity since
accumulation of poly-ubiquitinated proteins in Uchl3/ MEFs
(B) HEK293T cells expressing His-ubiquitin only or additionally Myc-TDP1 were treated with 20 mM MG132 for 4 hr, followed by lysis and purification of Myc-
tagged proteins usingMyc-trap beads. PurifiedMyc-TDP1 was incubated with BSA or recombinant UCHL3 for 4 hr at 30C. Samples were analyzed by anti-Myc
and anti-K48 immunoblotting.
(C) HEK293T cells were transfected with Myc-TDP1 and either empty GFP or a vector encoding UCHL3-GFP. Cells were treated with DMSO or 10 mM CPT for
20 min, followed by lysis and purification of GFP-tagged proteins using GFP-trap beads, and then analyzed by anti-Myc and anti-GFP immunoblotting.
(D) HEK293T cells were transfected with an empty vector ‘‘control’’ or plasmid encoding UCHL3-GFP, followed by incubation with 100 mg/mL cycloheximide
‘‘CHX’’ for the indicated time periods. Endogenous TDP1 were assessed by immunoblotting, normalized to actin, and the remaining TDP1 level was calculated
relative to levels prior to CHX incubations from three biological replicates and presented as average ± SEM.
(E) TDP1 levels were quantified from HEK293T cell lysates containing wild-type UCHL3 or the catalytically inactive UCHL3C95A mutant following incubation with
100 mg/mL CHX for the indicated time periods. Data represent the average of three biological replicates ± SEM.
(F) HEK293T cells containing Myc-TDP1 and His-ubiquitin were incubated with the UCHL3 inhibitor 1,3-indanedione (30675-13-9, Santa Cruz). Levels of
ubiquitinated proteins were purified by Ni-pull-down and analyzed by anti-Myc, anti-HA, and anti-actin antibodies. TDP1 ubiquitylation was quantified and is
presented as a percentage change relative to control cells transfected with Myc-TDP1 and His-ubiquitin from three biological replicates. *p < 0.05; **p < 0.01;
***p < 0.001; ns, p > 0.05; Student’s t test.
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Figure 5. TDP1 in Patient-Derived SCAN1 Cells Exhibits Elevated Ubiquitylation and Faster Turnover Rate
(A) HEK293T cells were transfected with plasmids encoding His-ubiquitin and Myc-TDP1, Myc-TDP1H493N, or Myc-TDP1H493R. Ubiquitinated proteins were
purified by Ni-pull-down and analyzed by anti-Myc immunoblotting.
(legend continued on next page)
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was attenuated by the exogenous expression of wild-type, but
not a hydrolase-deficient mutant (Setsuie et al., 2010). UCHL3
has been reported to deubiquitylate RAD51 and facilitates DSB
repair by homologous recombination (Luo et al., 2016).
This study provides an answer to the long-standing question
about why TDP1 levels in SCAN1 are reduced by 70%. We
reveal that the TDP1mutation in SCAN1 predisposes the enzyme
to higher ubiquitylation levels, due to the elevated formation of
transcription-blocking PDBs, which consequently accelerates its
proteasomal degradation (Figure 6D). Suppressing the increased
TDP1 ubiquitylation in SCAN1 cells by overexpression of UCHL3
was sufficient to restore TDP1 protein to levels comparable to
control cells. These findings unravel the importance of UCHL3 to
regulatechromosomal repair events thatareparticularly important
for themaintenance of the nervous system.Notably,UCHL3 is ex-
pressed in the brain and its deletion in mice has been reported to
cause neurodegeneration (Setsuie et al., 2009), retinal degenera-
tion (Sano et al., 2006), and significantmemory impairment (Wood
et al., 2005). Furthermore, using the senescence-accelerated
mouseprone8 (SAMP8)asamodel tostudycognitivedeclinedur-
ing aging, it hasbeen reported thatUCHL3 ismarkedlydownregu-
lated in the hippocampus; a critical brain region associated with
cognitivedeclineduringagingand variousneurodegenerative dis-
orders (Wang et al., 2008). These observations are particularly
attractive and consistent with our findings, since downregulation
of UCHL3 causes marked reduction in TDP1 levels and, conse-
quently, compromises the repair of transcription blocking PDBs,
the accumulation of which has been linked to neurodegeration
and premature aging (Garinis et al., 2009). It is therefore plausible
to propose that PDBs are elevated in the hippocampus of SAMP8
mice,providingamechanistic explanation for theneuronaldemise
associated with aging in this model. At the biochemical level, the
prominent accumulation of monoubiquitinated TDP1 in UCHL3
depleted cells suggests a preference for UCHL3 in clipping off
theentireubiquitin chain insteadofprocessivecleavage,which re-
mains to be tested in cell-free assays.
From the cancer point of view, UCHL3 is an attractive ‘‘drug-
gable’’ target and previous efforts focused on developing
UCHL3 inhibitors that specifically target UCHL3 in plasmodium
falciparumparasite, offeringpromising selectivity due to structural
differences compared to human UCHL3 (Artavanis-Tsakonas
et al., 2010). Here, we report that cancer cells overexpressing
TDP1, such as rhabdomyosarcoma, are associated with a
concomitant overexpression of UCHL3. Depletion of UCHL3 in
rhabdomyosarcoma cells reduced TDP1 levels and sensitized
cells to TOP1 poisons. Consistent with our data, UCHL3 overex-
pression in breast cancer has been correlated with poor survival
rates (Luo et al., 2016). Thus, UCHL3 inhibitionmay offer a worthy
therapeutic opportunity for cancer cells that possess upregulated
PDB repair mechanisms, particularly those that exploit this upre-
gulation as a mechanism to resist TOP1 targeting chemotherapy.
In summary, this study identifies UCHL3 as a regulator of chro-
mosomal SSB repair by controlling TDP1 proteostasis and high-
lights it physiological significance in neurological disease and
cancer.
EXPERIMENTAL PROCEDURES
Immunoprecipitation
HEK293Tcellswereplatedat13106per10-cmdishand transfectedusingstan-
dard calcium phosphate precipitation. Cells were lysed in buffer containing
50 mM Tris (pH 8), 0.5% Triton X, 40 mM NaCl, 2 mM CaCl2, 20 mM nethylma-
leimide, 13 protease inhibitor (Roche), 13 phosphatase inhibitor (Roche), and
25 U/mL Basemuncher (Expedeon). Lysates were kept on ice for 20 min before
clearing by centrifugation at 13,500 rpm at 4C for 15 min. Input samples were
kept at20C. Lysates were then adjusted to 150mMNaCl; anti-Myc antibody
was added (final concentration2 mg/mL); and sampleswere left rotating at 4C
for 1 hr. Protein G beads or GFP-Trap beads (chromotek) were washed three
times in wash buffer (20 mM Tris [pH 8], 150mMNaCl, and 20 mM nethylmalei-
mide) before the addition of lysate. Samples were then rotated overnight at 4C.
Beads were washed three times with wash buffer before resuspension in SDS
loading buffer for analysis by immunoblotting. If Ni-NTA (Expedeon) beads
were used for immunoprecipitation, lysates were adjusted to 150 mM NaCl
and 30mM imidazole.Wash buffer was also adjusted to 30mM imidazole, while
wash buffer containing 300 mM imidazole was used to elute bound proteins.
DUB Screen
A Human ON-TARGET plus siRNA library for all known DUBs (G-104705-05,
GE Life Sciences) was replated from 96- to 24-well formats and stored
(B) HEK293T cells were transfected with a plasmid encoding Myc-TDP1H493R and HA-tagged wild-type ubiquitin ‘‘WT’’ or ubiquitin mutant in which all lysines
were replaced by arginine ‘‘K0’’ or a mutant in which all lysines were replaced by arginine, except K48 ‘‘K48’’ or K63 ‘‘K63’’. HA immunoprecipitates were purified
using anti-HA antibodies and analyzed by anti-Myc immunoblotting.
(C) HEK293T cells were transfected with a plasmid encoding Myc-TDP1 H493R and empty vector ‘‘’’ or plasmids encoding His-ubiquitin ‘‘His-Ubi.’’ Cells were
treated with 50 mM DRB for 2 hr, and ubiquitinated proteins were purified by Ni-pull-down and analyzed by immunoblotting. TDP1 ubiquitylation was quantified
following normalization to TDP1 and is presented as an average a.u. ± SEM from three biological replicates.
(D) Control ‘‘WT’’ or SCAN1 human lymphoblastoid cells were incubated with 100 mg/mL CHX andmock treated with either DMSO ‘‘CPT’’ or 10 mMCPT ‘‘+CPT’’
for the indicated time periods. Endogenous levels of TDP1 were assessed by immunoblotting.
(E) SCAN1 cells (2.53 106) were incubated with 100 mg/mLCHX andmock treatedwith either DMSOor 20 mMMG132 for the indicated time periods. Endogenous
TDP1 was assessed by immunoblotting. Data represent the average of three biological replicates ± SEM.
(F) HEK293T cells expressingMyc-TDP1H493R andHis-ubiquitin were treatedwith 20 mMMG132 or DMSO for 4 hr. The ubiquitinated proteins were enriched using
Ni-pull-down, and ubiquitinated TDP1 was analyzed by anti-Myc immunoblotting.
(G) Control (23 107) ‘‘WT’’ human lymphoblastoid cells or 23 108 SCAN1 cells were lysed in ubiquitin binding buffer. 1 mg of WT lysate or 10 mg SCAN1 lysate
was incubated with 0.3 mL or 3 mL of the ubiquitin binding resin Multi-DSK, respectively. Multi-DSK-bound ubiquitinated proteins were purified by 300 mM
imidazole elution, and ubiquitinated proteins were subjected to TDP1 immunoprecipitation and ubiquitinated TDP1 analyzed by anti-TDP1 immunoblotting. TDP1
ubiquitylation was quantified, normalized to TDP1, and presented as an average a.u. ± SEM. Data are the average of three biological replicates.
(H) WT and SCAN1 cells were treated as described in (G). Lysates were incubated with Multi-DSK, and bound ubiquitinated proteins were subjected to TDP1
immunoprecipitation. Purified ubiquitylated TDP1 was incubated with BSA or recombinant UCHL3 for 4 hr at 30C and analyzed by anti-K48 immunoblotting.
(I) Lysates from control ‘‘WT’’ and SCAN1 cells were analyzed by immunoblotting. UCHL3 expression was normalized to tubulin and presented as a percentage
change in SCAN1 cells relative to control WT cells. Data are the average of three biological replicates ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05;
Student’s t test.
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Figure 6. UCHL3 Overexpression Restores the Level of TDP1 in Patient-Derived SCAN1 Cells
(A) Control wild-type ‘‘WT’’ and SCAN1 cells were transfected with empty EGFP plasmid or EGFP-UCHL3 plasmid encoding full-length UCHL3. Cell lysates were
analyzed by immunoblotting using anti-UCHL3, anti-TDP1, and anti-GFP antibodies (left). TDP1 protein expression level was quantified from three biological
repeats and presented as average relative to levels in control cells ± SEM (middle). Total RNAwas extracted from cells described in (A), followed by quantification
(legend continued on next page)
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at80C. 24-well plates were designed so that each would have a non-target-
ing control and TDP1 (transfection control) siRNA well. HEK293T cells were
plated at 1 3 106 per 10-cm dish and DNA transfected using calcium phos-
phate precipitation. 24 hrs after DNA transfection, siRNA library plates (24
well) were defrosted, and 100 mL of MEM (not supplemented) containing
0.5 mL Dharmafect 1 (GE Life Sciences) was added to each well and incubated
for 20 min. DNA-transfected cells were trypsinised, replated onto 24-well
plates at a density of 2.2 3 105/well, and incubated for a further 48 hr. Cells
were washed twice with 0.5 mL PBS; all PBS was removed before the addition
of 40 mL SDS loading buffer; and cells were vortexed 3 times for15 s. Lysates
were then boiled for 10 min and clarified by centrifugation at 10,000 3 g for
1 min. Samples were then analyzed by immunoblotting using an 8% gel and
anti-TDP1 antibody. Validation of putative hits was conducted by seeding
HEK293T cells in 6-well plates, followed by transfection of separate siRNA se-
quences and 4 pooled siRNA sequences against the hit, 24 hr later, using
DharmaFECT 1 Transfection Reagent (GE Dharmacon,T-2001-01). Cells
were lysed with SDS-PAGE and analyzed by immunoblotting.
Purification of Endogenous Ubiquitylated Proteins and In Vitro
Deubiquitination Assays
Cells were lysed in a buffer containing 50 mM Tris, 150 mM NaCl,
1.5 mM MgCl2, 5 mM EDTA, 10% Glycerol, 1% Triton, 13 phosphatase inhib-
itors, 13 protease inhibitors, 20 mM nethylmaleimide, 30 mM imidazole, and
25 U/mL Basemuncher (Expedeon). Protein concentrations of lysates were
determined using Bradford assay. 1 mL of MultiDSK reagent (1 mg/mL) (Kera-
fast) was added to every 1,300 mL of lysate and incubated on a rotator for
1 hr at 4C. NiNTA beads (Expedeon) were washed three times in lysis buffer
(minimum 103 bead volume) before lysates were transferred and left overnight
rotating at 4C. Ni-NTA beads were washed three times in wash buffer (lysis
buffer without nuclease) before bound complexes were eluted in 13 bead vol-
umewash buffer containing 300mM imidazole. Eluateswere adjusted to 30mM
imidazole using lysis buffer; 2 mg anti-TDP1 antibody was added; and samples
were rotated for 1 hr at 4C. Protein A beads were washed three times in 103
bead volume wash buffer before the addition of Ni eluate, and samples were
rotated at 4C for 3 hr. Protein A beads were washed three times in wash buffer
(20 mM Tris [pH 8], 150 mM NaCl, and 20 mM nethylmaleimide) before resus-
pension in 50 mL SDS loading buffer. Samples were then analyzed by immuno-
blotting using a 4%–12%gradient gel (BioRad TGX) and probedwith anti-TDP1
antibody. Smear intensities were quantified using ImageJ. For in vitro deubiqui-
tination assays, purified ubiquitylated TDP1 was incubated with 8.8 ng/mL BSA
or recombinant UCHL3 (Thermo Fisher Scientific,11634H07E5) for 4 hr at 30C
in a deubiquitination buffer (50mMTris-HCL [pH 8.0], 50mMNaCl,1mMEDTA,
10mMDTT, and 5%glycerol). Reaction products were analyzed by SDS-PAGE
and immunoblotting. For detection of endogenous ubiquitylated TDP1, cells
were lysed in 2% SDS, 150 mM NaCl, and 10 mM Tris-HCL (pH 8.0). Lysates
were incubated at 90C for 10 min, sonicated, and diluted 103 with dilution
buffer (10 mM Tris-HCL [pH 8.0], 150 mM NaCl, 2 mM EDTA, and 1% Triton),
followed by SDS-PAGE and immunoblotting.
Alkaline Comet Assays
Alkaline comet assays (ACAs) were essentially conducted as previously
described (Breslin et al., 2006). Briefly, HEK293T cells were transfected with
control siRNA or UCHL3 siRNA, and 48 hr later, cells (3 3 105 cells/sample)
were suspended in media containing 14 mMCPT or DMSO for 20 min at 37C.
Approximately 5,000 cells were mixed with equal volumes of PBS and 1.2%
type VII agarose at 42C, plated on frosted microscope slides pre-coated
with 0.6% agarose, and chilled until set. Cells were then lysed in 2.5 M
NaCl, 10 mM Tris-HCl, 100 mM EDTA [pH 8], 1% Triton X-100, and 1%
DMSO (pH 10) at 4C for 1 hr and washed twice with cold distilled water. Slides
were equilibrated in alkaline electrophoresis buffer (50 mM NaOH, 1 mM
EDTA, and 1% DMSO) for 45 min and then subjected to electrophoresis at
12 V (100 mA) for 25 min. DNA was then stained by SYBR Green (1:2,000,
Sigma S9430) for 5 min. Quantification of DNA breaks was performed using
Comet Assay IV software and counting 150 cells per sample.
Microarray Analyses
The dataset containing the microarray data from wild-type control and ataxia
telangiectasia patient cerebella was downloaded from the Gene Expression
Omnibus (https://www.ncbi.nlm.nih.gov/geo/) under the GEO accession
GSE61019 (Jiang et al., 2015). The data were then normalized, and differential
expression analysis was performed in R studio (R studio [v.1.0.136], R [v.3.3.2])
(Ritchie et al., 2015; Smyth, 2004). The microarray expression data were sub-
jected to log2 normalization and presented as log2 mRNA levels.
Experimental Repeats and Statistical Analyses
All data are presented as the means ± SEM of three experimental replicates,
unless otherwise stated. Statistical differences were analyzed using the Stu-
dent’s t test, with p < 0.05 considered to be statistically significant.
ACCESSION NUMBERS
The accession number for the raw data reported in this paper is Mendeley:
10.17632/rztbtg25zs.1. The accession number for the mass spectrometry
data reported in this paper is Mendeley:10.17632/hp9vrpp56z.1.
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